"99万一针抗癌针"上了热搜，但99%的讨论都停留在"中国便宜"这个浅层次结论上。真正值得问的是：同样是CAR-T，为什么中国能做到美国的1/3到1/5？这个价差到底差在了哪里？答案不是"中国劳动力便宜"，而是中美医疗体系在药价逻辑、住院成本、资源效率三个维度上的结构性差异。
"¥990,000 per injection cancer drug" went viral, but 99% of discussions停留在 the superficial conclusion that "China is cheap." The real question is: For the same CAR-T therapy, why can China do it for 1/3 to 1/5 of the US price? Where exactly does the price difference come from? The answer isn't "cheap Chinese labor" — it's the structural differences between the Chinese and American healthcare systems in three dimensions: drug pricing logic, hospitalization costs, and resource efficiency.
01
先讲三个真实的故事
THREE REAL STORIES FIRST
先讲三个真实案例，你大概就能感受到这件事的分量。 第一个：新西兰青年迈克，25岁。 原发性纵隔大B细胞淋巴瘤，在新西兰四线治疗全部失败——化疗、放疗、免疫、靶向，都没用。新西兰唯一的CAR-T临床试验他不符合入组条件。墨尔本的医院报价60万美元。他刚大学毕业，家里根本拿不出这笔钱。最后靠朋友众筹，飞到上海曜影医院做了阿基仑赛（CD19 CAR-T）。价格不到澳大利亚的一半。回输4周后PET-CT显示：完全缓解。 "在我最难受的时候，周医生会握着我的手给我力量。护士十秒钟就到。这些都是在新西兰难以想象的。"他说，甚至考虑以后搬到中国生活。 第二个：新西兰CEO乔西，59岁。 胃十二指肠腺癌，本国化疗+免疫治疗后病情持续进展，医生宣布继续化疗成功率只有15%。他在网上查到全球首款实体瘤CAR-T（CT041，舒瑞基奥仑赛）刚在中国获批。这款疗法，全球只有中国有。 他带着妻子和小儿子飞到上海嘉会国际医院。入院时伴有大量癌性腹水，每天引流1000-2000毫升，吃不了东西靠肠内营养维持。回输后第10天，恶性腹水开始消退。一个多月后顺利出院。总花费约99万元人民币（约13.7万美元）。 第三个：美国人丹尼尔。 肺癌，在美国四种治疗全部失败。MD安德森的医生直接说"我们这里没什么办法了"，但提到了一款新药依沃西（PD-1/VEGF双抗），是他最后的希望——但只在中国获批。他的子女都是医生，迅速联系到上海的医院。3月飞到上海治疗，期间出现免疫相关不良反应转入ICU，多学科会诊+该药主要研究者参与，最终转危为安。 这三个故事不是孤例。数据显示：2025年全国重点涉外医院接诊国际患者128万人次，较三年前增长73.6%，欧美患者数量翻了一番。CAR-T是其中增长最快、客单价最高的赛道之一。 那么问题来了——同样是CAR-T，为什么中国能做到美国价格的1/3甚至1/5？这个"价差"到底差在了哪里？
Let's start with three real cases so you can get a sense of the magnitude of this. First: Mike, 25, New Zealand. Primary mediastinal large B-cell lymphoma. All four lines of treatment failed in New Zealand — chemo, radiation, immunotherapy, targeted therapy, nothing worked. He didn't qualify for the only CAR-T clinical trial in New Zealand. A hospital in Melbourne quoted $600,000 USD. He'd just graduated, his family couldn't possibly afford it. Eventually, through friend crowdfunding, he flew to Shanghai's SinoUnited Hospital for axicabtagene ciloleucel (CD19 CAR-T). The price was less than half of Australia's quote. Four weeks after infusion, PET-CT showed: complete remission. "When I was feeling worst, Dr. Zhou would hold my hand and give me strength. Nurses arrived in ten seconds. These things are unimaginable in New Zealand." He says he's even considering moving to China. Second: Josh, 59, NZ CEO. Gastroduodenal adenocarcinoma. Disease progressed after chemo + immunotherapy in his home country; doctors said continued chemo had only 15% success rate. He found online that the world's first solid-tumor CAR-T (CT041, satricabtagene autoleucel) had just been approved in China. This therapy exists only in China. He flew to Shanghai Jiahui International Hospital with his wife and youngest son. On admission, he had massive malignant ascites, draining 1000–2000 mL daily, couldn't eat, maintained on enteral nutrition. Day 10 after infusion, malignant ascites began to recede. Discharged successfully after just over a month. Total cost approx. ¥990,000 RMB (~$137K USD). Third: Daniel, American. Lung cancer. Four lines of treatment all failed in the US. MD Anderson doctors basically said "there's nothing more we can do" — but mentioned a new drug, ivonescimab (PD-1/VEGF bispecific), as his last hope — but it's only approved in China. His children are all doctors; they quickly connected with a Shanghai hospital. Flew to Shanghai for treatment in March, had immune-related adverse events requiring ICU transfer, multi-disciplinary consultation plus the drug's principal investigator involved, ultimately stabilized. These three stories aren't isolated cases. Data shows: in 2025, key涉外 hospitals nationwide received 1.28 million international patients, up 73.6% from three years ago, European and American patient numbers doubled. CAR-T is one of the fastest-growing, highest-unit-price tracks. So the question is — for the same CAR-T therapy, why can China do it for 1/3 or even 1/5 of the US price? Where exactly does this "price gap" come from?
02
第一层差：药价（最大的一块）
LAYER 1: DRUG PRICE (THE BIGGEST PIECE)
先看最直观的对比——药价本身。
First, the most直观 comparison — the drug price itself.
CAR-T产品 / Product
美国定价 / US Price
中国定价 / China Price
差价倍数 / Ratio
Kymriah（诺华，ALL/淋巴瘤）
$475,000
¥120万 (~$16.5万)
约2.9倍
Yescarta（吉利德，淋巴瘤）
$373,000
¥120万 (~$16.5万)
约2.3倍
Carvykti（传奇生物，骨髓瘤）
$465,000
¥120万 (~$16.5万)
约2.8倍
合源生物纳基奥仑赛
—
¥99.9万 (~$13.8万)
国产最低价
CT041舒瑞基奥仑赛（实体瘤）
未获批 / N/A
¥99万 (~$13.7万)
全球首创
（价格为公开挂网/上市定价，实际因商保、谈判可能有浮动 / Prices are public list prices; actual may vary with insurance/negotiation）
为什么药价差这么大？核心是三个原因：
Why is the drug price gap so big? Three core reasons:
原因一：国产供应链把上游成本打下来了 CAR-T之所以贵，很大程度是因为它是"定制药"——每个患者的T细胞单独提取、单独改造、单独扩增，相当于一条生产线只生产一份产品。其中最贵的原材料是什么？慢病毒载体。 慢病毒是用来把CAR基因"植入"T细胞的载体，临床级别的病毒制备标准极高。以前全靠进口，单份病毒成本就高达数万甚至十万美元。 现在不一样了。中国生物医药供应链快速国产化——病毒载体、核心制备设备、细胞培养基、冻存物料，全部有了价格低得多的国产替代。以华道生物为例，把此前10万元/套的生产耗材降到了2000多元，是进口价的约1/50。 上游成本下来了，终端药价才能下来。
Reason 1: Domestic supply chain drove down upstream costs CAR-T is expensive largely because it's a "custom drug" — each patient's T cells are individually collected, engineered, expanded — equivalent to one production line making one product. What's the most expensive raw material? Lentiviral vectors. Lentivirus is the vector used to "implant" the CAR gene into T cells. Clinical-grade virus manufacturing standards are extremely high. Previously, all imported, single-batch virus costs alone could reach tens of thousands甚至 $100K+ USD. Now it's different. China's biopharma supply chain rapidly domesticated — viral vectors, core manufacturing equipment, cell culture media, cryopreservation materials — all have much cheaper domestic alternatives. Take Huadao Biotech for example: they reduced production consumables from ¥100K/set to ¥2,000+, about 1/50th of imported prices. When upstream costs come down, terminal drug prices can come down.
原因二：规模化生产+内卷竞争，把溢价挤没了 美国为什么贵？一个很重要的原因是寡头垄断。FDA批准的CAR-T产品只有几款，诺华、吉利德、BMS几家药企定价权很强。而且美国的医疗体系是"商业保险买单"，药企定价天然倾向于"保险公司能承受的上限"。 中国呢？NMPA已经批准了9款CAR-T产品（全球17款中国占了一半多），而且还在快速增加。复星凯特、药明巨诺、合源生物、驯鹿生物、恺兴生命、科济药业、传奇生物……你卖120万，我就卖99万；你做血液瘤，我就做实体瘤。 竞争激烈到什么程度？最新的国产CAR-T已经有喊出39.9万元的了。虽然不是所有产品都能做到这么低，但趋势很明确——价格还在往下走。 更狠的是产能。美国的CAR-T制备周期通常是3-5周，中国头部中心可以做到8-14天。全自动、全封闭、无人化产线正在建设，单厂年产能从300人份飙升到9000人份。规模越大，单人份成本越低。
Reason 2: Scale + competition squeezed out premium pricing Why is the US expensive? A key reason is oligopoly. The FDA has approved only a few CAR-T products; Novartis, Gilead, BMS have strong pricing power. And the US healthcare system is "commercial insurance pays," so pharma pricing naturally trends toward "the上限 insurers can bear." China? The NMPA has already approved 9 CAR-T products (China accounts for over half of the world's 17), and they're still increasing rapidly. Fosun Kite, JW Nektar, Heyuan Biotech, Xinyue Biotech, Kaixing, CARsgen, Legend Biotech… you sell for ¥1.2M, I sell for ¥990K; you do hematology, I do solid tumors. How intense is the competition? The latest domestic CAR-Ts are already quoting ¥399,000. Not all products can go that low, but the trend is clear — prices keep dropping. Even more impressive is production capacity. US CAR-T manufacturing typically takes 3–5 weeks; top Chinese centers can do it in 8–14 days. Fully automated, closed, unmanned production lines are being built, with annual per-factory capacity surging from 300 patient doses to 9,000. Larger scale = lower per-dose cost.
原因三：定价逻辑完全不同 美国药企的定价逻辑是"价值定价法"——你这个药能让患者多活几年、质量提升多少，折算成美元就是定价。Kymriah为什么敢卖47.5万美元？因为它能让原本只剩几个月的患者活四五年，折算成"质量调整生命年（QALY）"，这个价格是"合理"的。 中国的定价逻辑更接近"成本加成+市场竞争"——生产成本是多少，加上合理利润，再看看竞品卖多少钱，然后定一个能卖得动的价格。而且还有一个巨大的"天花板压力"：想进医保？先把价格打下来。业内潜规则是，高值创新药要纳入医保，价格需要降到30万元以内。 所以你会看到一个有意思的现象：同样的药，在美国是"按价值定价"（我能救你的命，所以我值这个价），在中国是"按成本+竞争定价"（我成本降下来了、竞争对手多了，所以我卖得便宜）。 👉 一句话总结药价差：美国贵是因为"垄断+价值定价+保险买单"，中国便宜是因为"国产替代+内卷竞争+医保压力"。这不是什么"中国偷工减料"，是两套完全不同的医疗体系运转出来的结果。
Reason 3: Completely different pricing logic US pharma pricing follows a "value-based pricing" logic — how many extra years of life does your drug give, how much quality improvement, converted to dollars is the price. Why does Kymriah dare to charge $475K? Because it can let patients who originally had months left live 4–5 more years; converted to "quality-adjusted life years (QALYs)," the price is "reasonable." China's pricing logic is closer to "cost-plus + market competition" — what's the production cost, add reasonable profit, check competitor pricing, then set a price that actually sells. And there's a huge "ceiling pressure": want to get into national insurance? Cut the price first. Industry insider rule: high-value innovative drugs need to drop below ¥300K to qualify for医保 negotiation. So you see an interesting phenomenon: the same drug, in the US it's "priced by value" (I can save your life, so I'm worth it), in China it's "priced by cost + competition" (my costs came down, there are more competitors, so I sell cheaper). 👉 One-line summary of drug price gap: US is expensive because "monopoly + value pricing + insurance pays"; China is cheaper because "domestic substitution + fierce competition + insurance pressure." This isn't "China cutting corners" — it's the result of two completely different healthcare systems operating.
03
第二层差：住院+护理费
LAYER 2: HOSPITALIZATION + NURSING COSTS
很多人只看到了"药价差3倍"，但真正恐怖的差距藏在住院和护理费里。 CAR-T治疗不是打一针就完了。整个流程包括： • 前期评估和检查（PET-CT、骨穿、病理复核、流式细胞术） • T细胞采集（单采） • 桥接治疗（如果需要，控制病情等细胞制备好） • 清淋化疗（回输前5-7天，为CAR-T腾位置） • CAR-T回输 • 回输后住院监测2-4周（CRS细胞因子风暴、ICANS神经毒性监测） • 如果副作用严重，需要进ICU • 后续随访 在美国，这一整套"非药费用"加起来，可能比药本身还贵。
Many people only see "3x drug price gap," but the truly terrifying gap is hidden in hospitalization and nursing costs. CAR-T treatment isn't just one injection. The full process includes: • Pre-treatment evaluation and testing (PET-CT, bone marrow biopsy, pathology review, flow cytometry) • T cell collection (leukapheresis) • Bridging therapy (if needed, to control disease while cells are manufactured) • Lymphodepleting chemo (5–7 days before infusion, to make space for CAR-T) • CAR-T infusion • 2–4 weeks inpatient monitoring post-infusion (CRS cytokine storm, ICANS neurotoxicity monitoring) • If severe side effects, ICU admission • Follow-up care In the US, all these "non-drug costs" combined can be more expensive than the drug itself.
费用项目 / Cost Component
中国（约）/ China (approx.)
美国（约）/ US (approx.)
倍数 / Multiple
CAR-T药物本身
$13.7万–$17.7万
$37万–$55万
2.7–3.1x
清淋化疗
$0.2万–$0.6万
$1万–$3万
5–6x
住院（含ICU监测）
$1.5万–$4万
$8万–$20万
5–6x
桥接治疗（如需）
$0.3万–$1.5万
$2万–$6万
5–7x
检查/影像/化验
$0.2万–$0.8万
$1.5万–$4万
6–7x
总计 / Total
$15万–$27万
$52.5万–$83万+
3.5–4x
（参考来源：ChinaMed Waypoint、JNCI Cancer Spectrum、PMC学术论文等公开数据整理，实际费用因个体差异浮动 / Sources: ChinaMed Waypoint, JNCI Cancer Spectrum, PMC academic papers, public data; actual costs vary by individual case）
住院费为什么差这么多？两个核心原因：
Why is hospitalization cost gap so big? Two core reasons:
第一，美国的住院和ICU是"天价"。 在美国，ICU一天的费用可以高达5000-10000美元，普通病房一天也要2000-3000美元。CAR-T治疗有近半数患者需要住ICU（因为细胞因子风暴的风险），住个一两周就是一辆车的钱没了。 中国呢？ICU一天大概3000-8000元人民币（约400-1100美元），普通病房一天几百到一千多。差距是5-10倍。 为什么？因为美国的医疗体系是"按服务付费"（fee-for-service），医院有动力把费用做高。而且美国医护人力成本极高——注册护士年薪七八万美元起，专科医生二三十万美元起。这些成本最终都转嫁到患者身上。
First, US hospitalization and ICU are "sky-high." In the US, ICU can cost $5,000–$10,000 USD per day, even a regular ward is $2,000–$3,000/day. Nearly half of CAR-T patients need ICU stay (due to cytokine release syndrome risk) — a week or two is a car's worth of money gone. China? ICU is about ¥3,000–8,000 RMB per day (~$400–$1,100 USD), regular ward is a few hundred to ~¥1,000+ per day. Gap is 5–10x. Why? Because the US system is "fee-for-service" — hospitals have incentive to drive up costs. And US healthcare labor costs are extremely high — registered nurses start at $70–80K/year, specialists $200–300K+. These costs ultimately get passed to patients.
第二，中国医院的效率更高、病人多、摊薄成本。 CAR-T这种治疗，做得越多越便宜。为什么？因为医护团队经验丰富了，并发症处理更熟练了，住院时间就短了，出问题的概率就低了。 中国头部CAR-T中心，一个中心一年就能做几百例。一些大医院的血液科，累计做过上千例。美国的顶尖中心，年收治量很多也就几十例。 量大会带来什么？经验、效率、成本优化。同样是CRS（细胞因子释放综合征），做过几百例的团队知道怎么快速识别、怎么精准用药、什么时候该进ICU什么时候不用——这直接决定了住院天数和花费。 《华尔街日报》报道过一个细节：澳大利亚患者迈克尔在上海治疗时，"护士十秒钟就到"。这背后的本质是——中国医院的床护比、医护响应速度，比很多发达国家的公立医院要好得多。
Second, Chinese hospitals are more efficient, more patients = lower per-case cost. Treatments like CAR-T get cheaper the more you do them. Why? Because the medical team gains experience, complication management becomes more skilled, hospital stays shorten, problem probability drops. Top Chinese CAR-T centers do hundreds of cases per year per center. Some large hospital hematology departments have done thousands cumulatively. Top US centers often do a few dozen a year. What does high volume bring? Experience, efficiency, cost optimization. Same CRS (cytokine release syndrome) — a team that's done hundreds knows how to quickly identify, how to precisely medicate, when to ICU and when not to — this directly determines length of stay and cost. The Wall Street Journal reported a detail: Australian patient Michael, during treatment in Shanghai, "nurses arrived in ten seconds." What's behind this? In Chinese hospitals, nurse-to-bed ratios and medical response speeds are much better than in many developed country public hospitals.
04
第三层差：时间（最贵的成本）
LAYER 3: TIME (THE MOST EXPENSIVE COST)
对癌症患者来说，时间是最贵的成本。很多人不是治不起，是等不起。 在美国做CAR-T，需要等多久？ • 找医院、排专家号：2-4周 • 保险审批（如果走保险）：2-6周，而且很多情况拒保 • 细胞制备：3-5周 • 排期回输：再等1-2周 全部加起来，从决定做到真正回输，可能要2-4个月。如果是公共医疗体系（英国、加拿大、澳大利亚），可能等半年甚至更久。 在中国呢？ • 国际部/私立医院：联系后24-48小时内回复，远程会诊1周内安排 • 签证：S2医疗签证1-3周（甚至有落地签便利） • 入院后评估+采集：1-2周 • 细胞制备：2-3周（头部中心8-14天） • 回输+监测：2-4周 从联系到回输，通常6-10周搞定。而且中国有个巨大的优势——病人多、排期快。美国可能一个中心一个月才做几个病人，中国的大中心一周就能做好几例。 这看似不是"钱"的问题，但对癌症患者来说，时间就是生命。晚一个月开始治疗，可能就是完全不同的结果。 曜影医院有个数据很说明问题：他们把海外评估到输注再到随访的全程压缩到了两个月以内。对很多晚期癌症患者来说，这两个月的时间差，可能就是"等得到治疗"和"等不到"的区别。
For cancer patients, time is the most expensive cost. Many people don't fail because they can't afford treatment — they fail because they can't wait. How long do you wait for CAR-T in the US? • Finding hospital, booking specialist: 2–4 weeks • Insurance approval (if going through insurance): 2–6 weeks, and many cases are denied • Cell manufacturing: 3–5 weeks • Scheduling infusion: another 1–2 weeks All together, from decision to actual infusion, could be 2–4 months. If public healthcare system (UK, Canada, Australia), could wait 6 months or even longer. In China? • International dept / private hospital: reply within 24–48 hours after contact, remote consultation arranged within 1 week • Visa: S2 medical visa 1–3 weeks (even landing visa便利 for some cases) • Admission evaluation + collection: 1–2 weeks • Cell manufacturing: 2–3 weeks (top centers 8–14 days) • Infusion + monitoring: 2–4 weeks From contact to infusion, usually done in 6–10 weeks. And China has a huge advantage — more patients = faster scheduling. A US center might do a few patients a month; top Chinese centers do several per week. This might not seem like a "money" issue, but for cancer patients, time is life. Starting treatment a month late could mean a completely different outcome. SinoUnited Hospital has a telling data point: they压缩 the entire process from overseas evaluation to infusion to follow-up to within two months. For many late-stage cancer patients, this two-month time difference could be the difference between "getting treatment in time" and "not making it."
05
还有第四层差：中国独有
LAYER 4: ONLY AVAILABLE IN CHINA
上面三层都是"同样的东西，中国更便宜"。但还有一个更重要的差距，很多人没意识到： 有些疗法，全世界只有中国有。 比如前面提到的CT041（舒瑞基奥仑赛）——全球首款实体瘤CAR-T，2026年6月22日在中国获批。胃癌、胰腺癌这些"癌中之王"，在全球范围内都没有太好的办法，现在中国率先有了。 新西兰患者乔西就是因为这个来的——他在本国没有更好的治疗方案了，这款新药是他最后的希望。而这款药，美国还没批，欧洲还没批，只有中国有。 再比如： • 依沃西（PD-1/VEGF双抗）：康方生物的全球首创双特异性抗体，肺癌、鼻咽癌等适应症效果显著，先在中国获批 • 卡度尼利（PD-1/CTLA-4双抗）：全球首个PD-1/CTLA-4双抗，治疗宫颈癌、胃癌等 • B7-H3 CAR-T治疗胶质母细胞瘤：北京天坛医院的临床研究，12个月总生存率66.7%，中位生存期19.1个月（历史数据仅6-8个月），其中一例完全缓解超过24个月 • 国产ADC、靶向药：很多针对中国高发癌种（鼻咽癌、肝癌、胃癌）的创新药，在中国先上市、先有真实世界数据 为什么会出现这种情况？因为中国做临床试验的速度快、病人多、成本低——一个新药从I期到上市，中国可能比美国快1-2年。再加上中国高发的癌种（胃癌、肝癌、鼻咽癌）在西方是"罕见病"，欧美药企研发动力不足，中国药企反而有动力投入。 这才是最有分量的"价差"——不是便宜不便宜的问题，是有没有的问题。你在美国再有钱，也买不到一个还没获批的药。而在中国，你可能提前2-3年用上全球最前沿的疗法。
The above three layers are all "same thing, cheaper in China." But there's an even more important gap many people don't realize: Some therapies exist only in China. Like the aforementioned CT041 (satri-cel) — the world's first solid-tumor CAR-T, approved in China June 22, 2026. Gastric cancer, pancreatic cancer — these "kings of cancers" — globally there haven't been good options. Now China is first to have one. New Zealand patient Josh came precisely for this — he had no better treatment options at home, this new drug was his last hope. And this drug isn't approved in the US, not in Europe — only in China. More examples: • Ivonescimab (PD-1/VEGF bispecific): Akeso Bio's world-first bispecific antibody, significant efficacy in lung cancer, NPC, etc., first approved in China • Candonilimab (PD-1/CTLA-4 bispecific): world's first PD-1/CTLA-4 bispecific, for cervical cancer, gastric cancer, etc. • B7-H3 CAR-T for glioblastoma: Beijing Tiantan Hospital clinical study — 66.7% 12-month OS, median OS 19.1 months (historical data only 6–8 months), one patient in CR for over 24 months • Domestic ADCs, targeted drugs: many innovative drugs for China-high-incidence cancers (NPC, liver, gastric) launch first in China, with real-world data first Why does this happen? Because China runs clinical trials faster, has more patients, lower costs — a new drug from Phase I to launch can be 1–2 years faster in China than the US. Plus, cancers common in China (gastric, liver, NPC) are "rare" in the West — Western pharma has less R&D incentive, Chinese pharma has more motivation to invest. This is the most significant "price gap" of all — it's not about cheap or expensive, it's about availability. No matter how much money you have in the US, you can't buy a drug that hasn't been approved. In China, you might get access to the world's most cutting-edge therapies 2–3 years earlier.
06
给家属和中介的实操建议
PRACTICAL ADVICE FOR FAMILIES & AGENTS
最后，给正在考虑来华做CAR-T的患者家属和渠道中介一些实操建议。
Finally, some practical advice for patient families and channel agents considering coming to China for CAR-T.
1. 先做远程预评估，不要人先飞过来 CAR-T不是所有人都能做的，有严格的适应症要求。比如CD19 CAR-T只对B细胞淋巴瘤/白血病有效，CT041只对CLDN18.2阳性的胃癌有效。在买票之前，一定先把完整病历、病理报告、近期影像、基因检测结果发给中国的医院，让医生先做远程评估，确认符合条件、还有治疗窗口期，再考虑过来。 避坑提醒：网上有些中介说"什么癌都能治、100%有效"——绝对是骗子。CAR-T是一种特定疗法，有严格的适应症。
1. Do remote pre-assessment first, don't fly over first CAR-T isn't for everyone — there are strict indication requirements. CD19 CAR-T only works for B-cell lymphoma/leukemia; CT041 only works for CLDN18.2-positive gastric cancer. Before buying tickets, definitely send complete medical records, pathology reports, recent imaging, genetic testing results to a Chinese hospital, let doctors do a remote assessment, confirm eligibility and that there's still a treatment window, then consider coming. Warning: Some online agents claim "any cancer can be treated, 100% effective" — those are definitely scammers. CAR-T is a specific therapy with strict indications.
2. 选对医院，比选药更重要 同样是CAR-T，不同医院做出来的效果和安全性可能差很多。选医院看三个指标： • 年输注量：量越大，经验越丰富，并发症处理越好。至少选择年输注量50例以上的中心。 • ICU配套能力：CAR-T有CRS/ICANS的风险，需要有经验的ICU团队托底。 • 国际患者服务体系：英文病历、多语种陪诊、签证支持、商保直付——这些服务能省很多事。 推荐方向（供参考，具体需匹配病情）： • 上海：瑞金医院（血液科全国顶尖）、嘉会国际（外籍患者最多的私立）、曜影医院（CAR-T经验丰富） • 北京：北大人民医院、301医院、北京肿瘤医院 • 广州：中山肿瘤（华南最强肿瘤中心）、复星禅诚（民营国际部完善） • 杭州：浙大邵逸夫医院（实体瘤CAR-T领先）
2. Choosing the right hospital matters more than choosing the drug Same CAR-T, different hospitals can have very different outcomes and safety profiles. Choose hospitals based on three metrics: • Annual infusion volume: more volume = more experience = better complication management. Choose centers with at least 50+ infusions/year. • ICU capability: CAR-T carries CRS/ICANS risks, needs experienced ICU backup. • International patient services: English medical records, multilingual accompaniment, visa support, direct insurance billing — these services save a lot of trouble. Recommended directions (reference only, match to specific condition): • Shanghai: Ruijin Hospital (top hematology), Jiahui International (most foreign patients private), SinoUnited (rich CAR-T experience) • Beijing: Peking University People's Hospital, 301 Hospital, Beijing Cancer Hospital • Guangzhou: SYSU Cancer Center (strongest in South China), Fosun Chancheng (well-established private international dept) • Hangzhou: Sir Run Run Shaw Hospital (leading in solid tumor CAR-T)
3. 预算要算"全周期"，不要只看药价 很多人只盯着99万、120万的药价，但实际总花费可能比这高。尤其是如果出现严重副作用需要进ICU，费用会往上跳。 比较靠谱的预算区间（外籍患者在华做CAR-T）：• 保守估计（顺利、无严重并发症）：110-160万人民币（约15-22万美元） • 中等估计（有轻度到中度并发症）：160-200万人民币（约22-28万美元） • 最坏情况（严重并发症、ICU时间长）：200万以上 注意：外籍患者在公立医院国际部的费用，通常比国内患者高1.5-2倍（因为有英文服务、专人协调、绿色通道等）。私立国际医院的价格更贵一些，但服务也更好。出发前一定要问清楚"报价包含什么、不包含什么"。 避坑提醒：如果有人给你报一个"打包价"远低于市场价，一定要警惕。正规医院不会随便报打包价，因为每个人的情况不一样。
3. Budget for the "full cycle," not just drug price Many people only focus on the ¥990K, ¥1.2M drug price, but actual total cost can be higher. Especially if severe complications require ICU, costs jump. Reliable budget range (foreign patients doing CAR-T in China):• Conservative estimate (smooth, no severe complications): ¥1.1M–¥1.6M RMB (~$150K–$220K USD) • Moderate estimate (mild to moderate complications): ¥1.6M–¥2M RMB (~$220K–$280K USD) • Worst case (severe complications, long ICU stay): ¥2M+ Note: Foreign patients at public hospital international departments usually pay 1.5–2x domestic rates (due to English services, dedicated coordinators, green channels, etc.). Private international hospitals are more expensive but have better service. Before departure, definitely clarify "what's included and what's not in the quote." Warning: If someone quotes you a "package price" far below market rate, be very wary. Reputable hospitals don't casually quote flat rates because every case is different.
4. 不要只看价格，"独有疗法"可能更有价值 如果你的情况在美国已经没有更好的方案了（比如多线治疗失败的胃癌、胰腺癌、胶质母细胞瘤），不要只盯着"中国更便宜"的血液瘤CAR-T。更值得关注的是中国独有、海外还没有的疗法： • 实体瘤CAR-T（CT041等） • 国产双抗药物（卡度尼利、依沃西等） • 国产ADC药物 • 各种在中国开展的临床试验 这些疗法可能不在美国保险的覆盖范围内，但它们可能是最后的希望。在做决定之前，找有经验的医生做一个全面的第二诊疗意见（second opinion），把所有可能的选项都列出来比较。
4. Don't just look at price — "exclusive therapies" may be more valuable If you've exhausted better options in the US (e.g., multi-line treatment failure for gastric, pancreatic cancer, glioblastoma), don't just fixate on "cheaper hematology CAR-T in China." What's more worth关注 are China-exclusive therapies not yet available overseas: • Solid tumor CAR-T (CT041, etc.) • Domestic bispecific antibodies (candonilimab, ivonescimab, etc.) • Domestic ADC drugs • Various clinical trials running in China These therapies may not be covered by US insurance, but they could be the last hope. Before deciding, get a comprehensive second opinion from an experienced doctor, list all possible options for comparison.
最后说一个判断： 美国患者飞来中国做CAR-T，这不是一个"图便宜"的故事——这是全球医疗格局正在发生变化的信号。 过去几十年，世界上最绝望的病人都会被告诉："去美国试试最贵的新疗法吧。"现在，这句话开始变成："去中国试试，那里可能有你要的药，而且更便宜、更快。" 价差的本质，不是"便宜"，是两套医疗体系的效率差： • 美国的体系擅长创新，但效率低、成本高、速度慢 • 中国的体系擅长把创新产业化、规模化、普惠化 99万一针还是很贵。但放在全球坐标里看——同样的疗效、更快的速度、1/3到1/5的价格、还有海外没有的独家疗法——对很多患者来说，这已经不是"值不值"的问题，而是"这是我唯一负担得起的机会"。
One final judgment: American patients flying to China for CAR-T — this isn't a "seeking cheap" story — it's a signal that the global medical landscape is changing. For decades, the world's most desperate patients were told: "Go to America and try the most expensive new therapy." Now, that sentence is becoming: "Try China — they might have the drug you need, and it's cheaper and faster." The essence of the price gap isn't "cheap" — it's the efficiency difference between two healthcare systems: • The US system excels at innovation, but is inefficient, high-cost, slow • China's system excels at industrializing, scaling, and democratizing innovation ¥990K per injection is still very expensive. But placed in a global coordinate system — same efficacy, faster speed, 1/3 to 1/5 the price, plus exclusive therapies not available overseas — for many patients, this isn't a question of "is it worth it" but rather, "this is the only opportunity I can afford."
免责声明：本文涉及的价格、数据、案例均来自公开渠道整理，仅供参考。具体诊疗方案和费用请以正规医疗机构的专业医生诊断和正式报价为准。CAR-T是一种高风险的前沿疗法，并非所有患者都适合，治疗前请务必咨询专业医生并充分评估风险。文中提及的医院和产品仅作行业分析示例，不构成医疗推荐。
Disclaimer: Prices, data, and cases in this article are compiled from public sources, for reference only. Specific treatment plans and costs should follow professional medical diagnosis and formal quotations from正规 medical institutions. CAR-T is a high-risk cutting-edge therapy, not suitable for all patients. Before treatment, please consult a professional doctor and fully assess risks. Hospitals and products mentioned are for industry analysis purposes only and do not constitute medical recommendations.
参考资料 / Reference
[1] 老外"反向"来中国抗癌重生！中国创新药的全球吸引力 上观新闻 2026年10月
[1] Foreigners "Reverse" Come to China for Cancer Recovery! Global Appeal of Chinese Innovative Drugs, Shangguan News, Oct 2026
[2] 一针99万元 外国人来中国抗癌 国际医疗成新增长点 中华网 2026年9月
[2] ¥990K per Injection, Foreigners Come to China for Cancer Treatment, International Medical Care Becomes New Growth Point, China.com, Sept 2026
[3] 从世界工厂到世界医院，老外集体来中国抗癌? 36氪 2026年9月
[3] From World Factory to World Hospital, Foreigners Collectively Come to China for Cancer Treatment? 36Kr, Sept 2026
[4] 全球首款实体瘤CAR-T疗法在杭应用 为美籍华人胃癌患者点燃希望 上观新闻 2026年10月
[4] World's First Solid Tumor CAR-T Therapy Applied in Hangzhou, Brings Hope to Chinese-American Gastric Cancer Patient, Shangguan News, Oct 2026
[5] CAR-T Therapy Cost in China for Lymphoma ChinaCureLink 2026
[5] CAR-T Therapy Cost in China for Lymphoma, ChinaCureLink, 2026
[6] How Much Does CAR-T Cost in China? ChinaMed Waypoint 2026
[6] How Much Does CAR-T Cost in China? ChinaMed Waypoint, 2026
[7] 华盛顿邮报：美国癌症患者正远赴中国购买救命药 央视环球资讯 2026年10月
[7] Washington Post: American Cancer Patients Traveling to China for Life-Saving Drugs, CCTV Global Info, Oct 2026
[8] 嘉会国际肿瘤中心：首位来华实体瘤CAR-T外籍患者顺利出院 嘉会官网 2026年8月
[8] Jiahui International Cancer Center: First Foreign Patient with Solid Tumor CAR-T Successfully Discharged, Jiahui Official, Aug 2026
[9] Total Costs of CAR-T Immunotherapy PMC (美国学术研究) 2018
[9] Total Costs of CAR-T Immunotherapy, PMC (US academic study), 2018
[10] China's innovative therapies lead new cancer battle China Daily 2026年10月
[10] China's Innovative Therapies Lead New Cancer Battle, China Daily, Oct 2026
[11] 花钱最狠的老外，排队住进中国医院 36氪 2026年9月
[11] The Biggest-Spending Foreigners, Queuing Up to Enter Chinese Hospitals, 36Kr, Sept 2026
